Literature DB >> 17412447

Methodology of superiority vs. equivalence trials and non-inferiority trials.

Erik Christensen1.   

Abstract

The randomized clinical trial (RCT) is generally accepted as the best method of comparing effects of therapies. Most often the aim of an RCT is to show that a new therapy is superior to an established therapy or placebo, i.e. they are planned and performed as superiority trials. Sometimes the aim of an RCT is just to show that a new therapy is not superior but equivalent to or not inferior to an established therapy, i.e. they are planned and performed as equivalence trials or non-inferiority trials. Since the types of trials have different aims, they differ significantly in various methodological aspects. The awareness of the methodological differences is generally quite limited. This paper reviews the methodology of these types of trials with special reference to differences in respect to planning, performance, analysis and reporting of the trial. In this context the relevant basal statistical concepts are reviewed. Some of the important points are illustrated by examples.

Mesh:

Year:  2007        PMID: 17412447     DOI: 10.1016/j.jhep.2007.02.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  Comparison of diagnostic accuracy and interpretation times for a standard and an advanced 3D visualisation technique in CT colonography.

Authors:  Thomas Mang; Frank T Kolligs; Claus Schaefer; Maxmilian F Reiser; Anno Graser
Journal:  Eur Radiol       Date:  2010-10-03       Impact factor: 5.315

2.  Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials.

Authors:  Antonio Facciorusso; Francesco Bellanti; Rosanna Villani; Veronica Salvatore; Nicola Muscatiello; Fabio Piscaglia; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  United European Gastroenterol J       Date:  2016-10-03       Impact factor: 4.623

Review 3.  Clinical trial design in biosimilar drug development.

Authors:  G Dranitsaris; K Dorward; E Hatzimichael; E Amir
Journal:  Invest New Drugs       Date:  2012-11-17       Impact factor: 3.850

4.  Virtual reality by mobile smartphone: improving child pedestrian safety.

Authors:  David C Schwebel; Joan Severson; Yefei He; Leslie A McClure
Journal:  Inj Prev       Date:  2016-09-01       Impact factor: 2.399

5.  Use of Placebo in Clinical Trials of Psychotropic Medication.

Authors:  Mehrul Hasnain; Abraham Rudnick; Weldon S Bonnell; Gary Remington; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2018-05       Impact factor: 4.356

6.  Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence.

Authors:  Andrea Messori; Valeria Fadda; Dario Maratea; Sabrina Trippoli; Roberta Gatto; Mauro De Rosa; Claudio Marinai
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-12       Impact factor: 5.346

7.  Modelling of the outcome of non-inferiority trials by integration of historical data.

Authors:  Alberto Russu; Erik van Zwet; Giuseppe De Nicolao; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-21       Impact factor: 2.745

8.  Portable monitoring and autotitration versus polysomnography for the diagnosis and treatment of sleep apnea.

Authors:  Richard B Berry; Gilbert Hill; Linda Thompson; Valorea McLaurin
Journal:  Sleep       Date:  2008-10       Impact factor: 5.849

9.  Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate.

Authors:  Jae Hyuck Chang; In Seok Lee; Hyung Keun Kim; Yu Kyung Cho; Jae Myung Park; Sang Woo Kim; Myung-Gyu Choi; In-Sik Chung
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

10.  Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study.

Authors:  Marilee Carballo; Mary S Maish; Dawn E Jaroszewski; Carmack E Holmes
Journal:  J Cardiothorac Surg       Date:  2009-02-24       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.